Growth for the firm's core lab and pathology lab businesses was offset by a decline in molecular diagnostics and near patient care in the first nine months of the year.

The firm said it will develop a test for use at home and at the point of care to aid the diagnosis of syphilis and distinguish between active and past infections.

The Houston-based firm is set to scale up its Flu/Covid test manufacturing for the current respiratory virus season.

Quest has developed a multi-target molecular test for avian influenza A H5 virus that it plans to make available by the end of October.

NEW YORK – The Advanced Research Projects Agency for Health (ARPA-H) announced on Wednesday $110 million in awards given to 23 commercial and academic entities as part of its Sprint for Women's Health ...

The Maryland-based firm said that the money will support the development and commercialization of a screening test for esophageal squamous cell carcinoma.

NEW YORK – Danaher reported a 3 percent year-over-year increase in third quarter revenues on Tuesday even as the firm reported softness in China for its life sciences and diagnostics segments..

CEO Jim Davis said the company is on track to close eight lab acquisition deals this year, though he added that it is now in an "integration and digestion" phase.

NEW YORK – After receiving 510 (k) clearance early this month from the US Food and Drug Administration for its sepsis test, Swiss diagnostics company Abionic is targeting the US for further ...

The company reported revenues of $2.49 billion, up from $2.30 billion in the year-ago period and above the consensus Wall Street estimate of $2.42 billion.

Last week, readers were most interested in a story about how priorities for the lab industry could play out depending on election results.